Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with <i>N</i>-Dimethylnitrosamine-Induced Liver Cirrhosis

Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with <i>N</i>-Dimethylnitrosamine-Induced Liver Cirrhosis

Tofacitinib, a Janus kinase 1 and 3 inhibitor, is used to treat rheumatoid arthritis. It is mainly metabolized by the cytochromes p450 (CYP) 3A1/2 and CYP2C11 in the liver. Chronic inflammation eventually leads to cirrhosis in patients with rheumatoid arthritis. Isosakuranetin (ISN), a component of...

Full description

Bibliographic Details
Main Authors: Sung Hun Bae, Hyeon Gyeom Choi, So Yeon Park, Sun-Young Chang, Hyoungsu Kim, So Hee Kim
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceutics
Subjects:
tofacitinib
liver cirrhosis
isosakuranetin
pharmacokinetics
CYP3A1/2
CYP2C11
Online Access:https://www.mdpi.com/1999-4923/14/12/2684

Internet

https://www.mdpi.com/1999-4923/14/12/2684

Similar Items